Colon cancer is the second leading cause of cancer death in the United States (1). Colon carcinogenesis involves stepwise, progressive disruption of intestinal epithelial cell proliferation, differentiation, and survival mechanisms (2). Protein kinase C (PKC) 1 is a family of lipid-dependent serine/threonine kinases involved in the regulation of cell proliferation, differentiation, and survival (3, 4). Specific, reproducible changes in PKC isozyme expression patterns occur during carcinogen-induced colon carcinogenesis in rodents (5, 6). We recently demonstrated reduced expression of PKC␣ and increased expression of PKC␤II and PKC in AOM-induced mouse colon tumors (7, 8) . Our subsequent studies provided direct evidence that both PKC␤II and PKC play critical, but distinct, roles in the promotion of colon carcinogenesis (8 -10).
1 is a family of lipid-dependent serine/threonine kinases involved in the regulation of cell proliferation, differentiation, and survival (3, 4) . Specific, reproducible changes in PKC isozyme expression patterns occur during carcinogen-induced colon carcinogenesis in rodents (5, 6) . We recently demonstrated reduced expression of PKC␣ and increased expression of PKC␤II and PKC in AOM-induced mouse colon tumors (7, 8) . Our subsequent studies provided direct evidence that both PKC␤II and PKC play critical, but distinct, roles in the promotion of colon carcinogenesis (8 -10) .
We have developed transgenic PKC␤II mice that express elevated PKC␤II in the colonic epithelium (9, 10) . Transgenic PKC␤II mice exhibit hyperproliferation of the colonic epithelium and are prone to AOM-induced colon cancer (9, 10) . This cancerprone phenotype results, at least in part, from the establishment of a PKC␤II-dependent hyperproliferative phenotype (9, 10) . We have also established nontransformed rat intestinal epithelial (RIE) cell lines that overexpress PKC␤II (RIE/PKC␤II cells) (10, 11) . Genomic analysis of RIE/PKC␤II cells demonstrated that PKC␤II induces expression of the Cox-2 enzyme and suppresses expression of the transforming growth factor ␤ receptor type II (TGF␤RII) (11) . As a result, RIE/PKC␤II cells no longer respond to the growth-inhibitory effects of TGF␤ (11) . Further analysis revealed that PKC␤II-mediated loss of TGF␤ responsiveness requires the activity of both PKC␤II and Cox-2 (11) . Based on these data, we defined a novel, procarcinogenic PKC␤II 3 Cox-2 3 TGF␤RII signaling pathway by which PKC␤II confers resistance to TGF␤ (11) . This pathway contributes to the hyperproliferative phenotype exhibited by transgenic PKC␤II mice (11) . This PKC␤II-mediated pathway is activated by carcinogens, whereas chemopreventive -3 fatty acids inhibit PKC␤II activity, suppress PKC␤II-mediated hyperproliferation, and attenuate the cancer-prone phenotype exhibited by transgenic PKC␤II mice (10, 11) .
PKC␤II also induces an invasive phenotype in RIE cells through activation of a novel proinvasive PKC␤II 3 Ras 3 PKC/Rac1 3 MEK signaling pathway that is distinct from that responsible for TGF␤ resistance (12) . Thus, PKC␤II promotes AOM-induced colon cancer through activation of at least two distinct signaling pathways, one that confers TGF␤ resistance and a second that induces invasion in intestinal epithelial cells. Here we resolve two critical questions regarding PKC␤II and colon carcinogenesis. First, we provide direct evidence that PKC␤II expression is both necessary and sufficient for AOMinduced colon carcinogenesis. Second, we identify a major mechanism by which PKC␤II expression is regulated in the colonic epithelium. Our results demonstrate that PKC␤II induces its own expression in RIE and human colon cancer cells in vitro and in the colonic epithelium in vivo. PKC␤II autoregulation is dependent upon PKC␤II activity and is mediated predominantly through transcriptional activation of the PKC␤ promoter through a PKC␤II-, MEK-dependent signaling pathway. Our results suggest that PKC␤II autoregulation plays a key promotive role in carcinogen-induced colon cancer.
EXPERIMENTAL PROCEDURES
Transgenic Mice and Carcinogenesis Studies-Mice nullizygous for PKC␤ (PKC␤KO mice) were generated and characterized previously (13) . Transgenic PKC␤II mice, which express PKC␤II in the colonic epithelium, were generated and characterized previously (9, 10) . PKC␤KO and transgenic PKC␤II mice on a C57B6 genetic background were crossed to obtain PKC␤KO/PKC␤II mice. Genotyping was performed as described previously (9, 13) . Wild-type, PKC␤KO, and PKC␤KO/PKC␤II mice were treated with AOM to induce colon carcinogenesis and assessed for ACF as described previously (9) .
Cell Culture and Immunoblot Analysis-RIE cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 5% fetal bovine serum as described previously (8, 10 -12) . RIE cells stably expressing human PKC␤II were generated and maintained as described previously (10) . The established human HCT116 and HT-29 colon cancer cell lines were obtained from the American Tissue Type Culture Collection and maintained in McCoy's 5a medium (Invitrogen) with 1.5 mM L-glutamine and 10% fetal bovine serum. Whole cell extracts were prepared and subjected to immunoblot analysis as described previously (10 -12) . Antibodies specific to PKC␤II and ␤-actin were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-FLAG antibody was from Sigma. Antigen antibody complexes were visualized using the ECL Western blotting detection system (Amersham Biosciences) as described previously (10 -12) . LY317615 was kindly provided by Lilly. In some cultures, LY317615 was added to a final concentration of 25 M. This concentration was chosen based on the reported IC50 (3.5 M) of this compound to inhibit PKC␤ signaling in SW2 small cell lung carcinoma cells in culture (14) . In some cultures, the selective MEK1 and -2 inhibitor U0126 (10 M; Calbiochem), PD98059 (30 M; Sigma), or the Cox-2 inhibitor celecoxib (25 M) was added as described previously (12) .
Isolation of Colonic Crypts, RNA Isolation, and Quantitative Real Time PCR (QRT-PCR)-Enriched populations of mouse colonic epithelial and mesenchymal cells were isolated from wild-type and transgenic PKC␤II mice essentially as described (15) . A detailed description of this procedure will be published elsewhere. 2 Briefly, the entire colon was isolated from mice as described previously (9) . Colons were everted and washed with Hepes-buffered saline (25 mM Hepes, pH 7.5, 150 mM NaCl) supplemented with 1% fetal bovine serum. Colonic crypts enriched in epithelial cells were released by incubation in Hepes-buffered saline containing 10 mM EDTA, and isolated crypts were collected by centrifugation. Mesenchymal cells were isolated by gentle scraping from the remaining colon tissue using a plastic slide coverslip. Total RNA was isolated using RNAqueous reagent (Ambion), treated with DNase for 15-30 min, and subjected to RT-PCR analysis as described previously (8, 11) .
QRT-PCR was carried out using target-specific probes and primers to detect PKC␤IIa (probe spanning exons 16 and 17 of the human PKC␤ gene), PKC␤I (probe spanning exons 16 and 18) , and PKC␤I and PKC␤IIb (probes internal exon 18) mRNA species. PKC␤ reagents were generated using the Assay by Design program from Applied Biosystems, Inc., and were validated by demonstrating a linear relationship between ⌬Ct and cDNA concentration over a wide range of sample concentrations. Commercially available, validated primer and probe sets for mouse E-cadherin and vimentin were from Applied Biosystems (Assays on Demand). Data were normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA abundance to control for RNA concentration. Standard curves were established using serial dilution of a reference sample. TaqMan Universal PCR Master Mix, murine leukemia virus reverse transcriptase, and RNase inhibitor were used (PerkinElmer Life Sciences). Amplification data were collected using an Applied Biosystems Prism 7900 sequence detector and analyzed using the Sequence Detection System software from Perkin Elmer Life Sciences.
Kinase-deficient Mutant of Human PKC␤II Mutation and Retrovirus
Transfection-A kinase-deficient mutant of human PKC␤II (kdPKC␤II) was generated by PCR-based site-directed mutagenesis to mutate lysine 372 of PKC␤II, a residue essential for ATP binding and kinase activity, to tryptophan using the QuikChange XL site-directed mutagenesis Kit (Stratagene) as described previously (12) . The kdPKC␤II mutant was inserted into the pBabe/Flag/puro retroviral expression vector, and virus stocks were produced using Phoenix-E cells. Puromycin-resistant, stable transfectants were generated as described previously (12) . Expression of PKC␤II or kdPKC␤II was confirmed by immunoblot analysis using anti-FLAG and anti-PKC␤II antibodies as described previously (12) . Mid-log phase cultures were used for all experiments unless otherwise specified.
Cloning and Characterization of the Human PKC␤ Promoter-Two PKC␤ promoter constructs consisting of 2.3 kb (pkc␤-2.3) and 500 bp (pkc␤-0.5) of 5Ј-flanking sequence were cloned by PCR from a human genomic DNA library using the Genome Walker Kit (BD Biosciences, Clontech). The resultant PCR products were confirmed by sequencing and found to correspond to the sequence reported in the public human genome sequence data base. Promoter constructs were cloned into the luciferase reporter vector pGL3 (Promega) to yield pPKC␤/luc reporters. Promoter activity was assayed by co-transfection of 1 g of pGL3-pkc␤-0.5 or pGL3-pkc␤-2.3 plus 50 ng of phRL-SV40 into RIE, HCT116, and HT-29 cells using the FuGene6 lipofection reagent (Roche Applied Science) as described by the manufacturer. 24 h after transfection, cells were assayed for firefly and Renilla luciferase activity using a dual luciferase assay system (Promega) as described previously (11) . Results are expressed as firefly luciferase activity normalized to Renilla luciferase, which served as a control for transfection efficiency.
RESULTS

Expression of PKC␤II in the Colonic Epithelium Is Necessary and Sufficient to Confer Susceptibility to Colon Carcinogenesis-
The impetus for studying the regulation of PKC␤II expression in the colonic epithelium comes from our observation that PKC␤II expression is elevated in colonic preneoplastic lesions, ACF, and colon tumors of mouse exposed to the chemical carcinogen azoxymethane (7) . Furthermore, transgenic PKC␤II mice expressing elevated PKC␤II in the colonic epithelium to levels consistent with those observed in AOM-induced colon tumors exhibit hyperproliferation of the colonic epithelium and increased sensitivity to AOM-induced colon carcinogenesis (9) . Thus, PKC␤II levels correlate with colon carcinogenesis, and elevation of PKC␤II levels by transgenesis leads to a cancerprone phenotype. However, a remaining question was whether PKC␤II expression was necessary for AOM-induced colon carcinogenesis. To address this question, we determined the susceptibility of PKC␤KO mice (13) to AOM-induced colon carcinogenesis ( Fig. 1) .
Wild-type and PKC␤KO mice were treated with AOM to induce colon carcinogenesis and assessed for development of ACF as described previously (9) . ACF are considered preneoplastic lesions, and their number is highly predictive of subsequent colon tumor formation (16, 17) . PKC␤KO mice exhibit a statistically significant, 3-fold decrease in ACF formation when compared with wild-type mice. These results demonstrate that expression of PKC␤II is an important determinant of susceptibility to AOM-induced colon carcinogenesis. We next assessed the role of PKC␤II expression in the colonic epithelium in susceptibility to colon carcinogenesis. For this purpose, PKC␤KO mice were crossed to transgenic PKC␤II mice to generate PKC␤KO/PKC␤II mice. PKC␤KO/PKC␤II mice are nullizygous for the PKC␤ gene by virtue of the germ line disruption of the endogenous PKC␤ gene (13) . However, these mice are capable of expressing PKC␤II only in the colonic epithelium due to the presence of transgenic human PKC␤II, whose expression is restricted to the colonic epithelium (9) . When PKC␤KO/PKC␤II mice are treated with AOM, ACF formation is restored to levels indistinguishable from wild-type mice. These data demonstrate that expression of PKC␤II within the colonic epithelium is both necessary and sufficient to confer susceptibility to AOM-induced colon carcinogenesis.
Expression of Human PKC␤II in RIE Cells Induces Expression of Endogenous PKC␤II-Since PKC␤II expression in the colonic epithelium is an important determinant of colon cancer susceptibility, we next assessed the mechanism by which PKC␤II expression is regulated. An important clue came from a genomic analysis of RIE and RIE/PKC␤II cells for potential PKC␤II gene targets. This analysis revealed that the endogenous rat PKC␤ gene is induced by the presence of human PKC␤II (data not shown). To confirm these results, we generated real time PCR reagents that detect rat PKC␤ mRNA species but not the human PKC␤II transgene. Alternative splicing of PKC␤ mRNAs is complicated, with evidence of tissue-specific differences in splice patterns (18 -20) . The PKC␤ gene can be alternatively spliced to produce at least three mRNA splice variants termed PKC␤I, PKC␤IIa, and PKC␤IIb (20) (Fig. 2A) . To determine whether PKC␤II induces expression of a specific splice variant of the endogenous PKC␤ gene, we developed PCR reagents to detect each of these splice variants and determined the level of each variant by quantitative real time PCR in RIE and RIE/PKC␤II cells (Fig. 2B) . Whereas RIE cells contain no detectable PKC␤ mRNA species, RIE/ PKC␤II cells express abundant endogenous PKC␤IIa and PKC␤IIb mRNA but no detectable PKC␤I mRNA. The pattern of expression of the three splice variants of PKC␤ is very similar to the pattern of expression of these variants in rat brain, a very abundant source of PKC␤I and PKC␤II mRNA. In contrast to RIE/PKC␤II cells, RIE cells transfected with a kinase-deficient mutant of PKC␤II (RIE/kdPKC␤II cells) express no detectable rat PKC␤ mRNAs. Taken together, these data demonstrate that PKC␤II induces expression of PKC␤II. The PKC␤IIa mRNA species is the major form produced, with lower but detectable amounts of the PKC␤IIb mRNA. PKC␤II autoinduction requires the kinase activity of PKC␤II, since kdPKC␤II does not induce endogenous PKC␤ expression.
Immunoblot analysis of total cell extracts from RIE and RIE/PKC␤II cells with a specific antibody to PKC␤II revealed, as expected (12) , that RIE cells express no detectable PKC␤II protein (Fig. 2C) . In contrast, two immunoreactive bands corresponding to PKC␤II are detected in RIE/PKC␤II cells. Immunoblot analysis with an anti-FLAG antibody confirmed the identity of the slower migrating band as transgenic FLAGtagged human PKC␤II. The faster migrating band is not recognized by the anti-FLAG antibody and co-migrates with rat brain PKC␤II, indicating that it corresponds to endogenous rat PKC␤II. Immunoblot analysis using a PKC␤I-specific antibody revealed no detectable PKC␤I protein in RIE or RIE/PKC␤II cells (data not shown). These results indicate that expression of PKC␤II in RIE cells induces endogenous PKC␤II mRNA and protein.
PKC␤II Activates the Human PKC␤ Promoter-PKC␤II-mediated induction of PKC␤II expression could be caused by multiple mechanisms, including activation of transcription of the PKC␤ gene and stabilization of the PKC␤II mRNA. To distinguish between these mechanisms, we next determined the halflife of the PKC␤II mRNA in RIE/PKC␤II cells as described previously (11) . We obtained a half-life of Ͼ24 h (data not shown), consistent with the reported half-life of PKC␤II in other cells (18) . However, we were unable to detect PKC␤II mRNA in RIE cells, making a comparison of half-life in the presence and absence of PKC␤II impossible. Therefore, we cannot eliminate the possibility that stabilization of the PKC␤II mRNA contributes to PKC␤II-mediated induction of PKC␤II mRNA and protein.
We next determined whether PKC␤II induces the activity of the human PKC␤ promoter. For this purpose, we cloned two promoter constructs consisting of 500 bp and 2.3 kb from the PKC␤ gene from a genomic DNA library from K562 human myelocytic leukemia cells. The PKC␤ promoter is extremely GC-rich in the immediate 5Ј region upstream of the transcriptional start site, making it a prime candidate for methylationmediated gene silencing. In addition, the promoter does not contain a conventional TATA box. When these PKC␤ promoter constructs are placed in front of a luciferase reporter plasmid and transfected into RIE and RIE/PKC␤II cells, both constructs exhibit a 3-5-fold induction in the presence of PKC␤II (Fig. 3A) . We recently demonstrated that PKC␤II activates cellular K-Ras in RIE/PKC␤II cells (12) . As a consequence of K-Ras activation, PKC␤II induces PKC-, Rac1-, and MEK-dependent invasion of these cells (12) . The human PKC␤ promoter was previously shown to be activated by phorbol esters through AP1 and AP2 elements within the promoter (21) . Therefore, we assessed whether PKC␤II-dependent activation of the PKC␤ promoter requires Ras/MEK-dependent signaling (Fig. 3B) . The two MEK1 and -2 inhibitors, U0126 and PD98059, both cause significant inhibition of PKC␤ promoter activity in RIE/PKC␤II cells.
We recently demonstrated that PKC␤II also induces the expression of the Cox-2 enzyme in RIE/PKC␤II cells (11) . However, the selective Cox-2 inhibitor celecoxib had no effect on PKC␤ promoter activity in RIE/PKC␤II cells, indicating that Cox-2 is not involved in PKC␤II-mediated induction of the PKC␤ promoter. To confirm the involvement of MEK in the regulation of PKC␤II expression, we determined the effect of U0126 and PD98059 on expression of endogenous PKC␤II mRNA in RIE/PKC␤II cells (Fig. 3C) . Both U0126 and PD98059 significantly repressed PKC␤II mRNA expression in RIE/PKC␤II cells, whereas 25 M celecoxib had no effect on PKC␤II mRNA despite the fact that this concentration of celecoxib completely blocks PKC␤II-mediated repression of TGF␤RII (11) . These results demonstrate that PKC␤II induces its own expression in RIE/PKC␤II cells through a MEK-dependent signaling pathway.
PKC␤ Promoter Activity Correlates with PKC␤II Expression in Human Colon
Cancer Cells-We next determined whether activation of the PKC␤ promoter could be responsible for regulating the expression of PKC␤II in human colon cancer cells. FIG. 1 . PKC␤II in the colonic epithelium is necessary and sufficient to confer sensitivity to colon carcinogenesis. Wild-type, nullizygous PKC␤ (PKC␤KO) and compound transgenic PKC␤KO/ PKC␤II mice were treated with AOM to induce colon carcinogenesis as described previously (8, 9) . 12 weeks after AOM exposure, mice were analyzed for formation of aberrant crypt foci (ACF) in the colon as described previously (8, 9) . Data represent the mean number of ACF/ mouse Ϯ S.E. PKC␤KO mice exhibit a significant decrease in ACF formation when compared with wild-type or PKC␤KO/PKC␤II mice (*, p Ͻ 0.02).
For this purpose, we assessed PKC␤ promoter activity in human colon cancer cells that express different levels of endogenous PKC␤II. Immunoblot analysis of HT29 and HCT116 cells demonstrate that HT29 cells express very little PKC␤II, whereas HCT116 cells express much higher levels of PKC␤II (Fig. 4A) . The relative level of PKC␤II protein expression correlates well with the steady state levels of PKC␤II mRNA in these two cell lines, since HCT116 cells express ϳ10-fold more PKC␤II mRNA than HT29 cells (Fig. 4B) . Transfection of the human PKC␤ promoter into HT29 and HCT116 cells revealed that the activity of both the 500-bp and 2.3-kb PKC␤ promoters was 10 -15-fold higher in HCT116 cells than in HT29 (Fig. 4C) , consistent with the difference in endogenous PKC␤II mRNA and protein levels in these cells. Thus, PKC␤ promoter activity directly correlates with the steady state levels of PKC␤II mRNA and protein in two established human colon cancer cell lines. Similar results were obtained in Caco2 and DLD-1 cells that express low and high PKC␤II levels, respectively. These data indicate that PKC␤II expression is controlled, at least in part, through transcriptional regulation of the PKC␤ gene in a variety of human colon cancer cells.
We next determined whether PKC␤II regulates the activity of its own promoter and mRNA levels in human colon cancer cells. HT29 and HCT116 cells were transfected with the 500-bp human PKC␤ promoter construct and treated with either the PKC␤-selective inhibitor LY317615 or the MEK1 and -2 inhibitor U0126 (Fig. 5A) . Both LY317615 and U0126 caused significant inhibition of PKC␤ promoter activity in HCT116 cells, consistent with our results in RIE/PKC␤II cells. In contrast, HT29 cells, which express very low endogenous PKC␤II, exhibit very low PKC␤ promoter activity that is not inhibited by either LY317615 or U0126. Thus, the ability of LY317615 to inhibit PKC␤ promoter activity correlates directly with PKC␤II expression in HCT116 and HT29 cells, indicating that
FIG. 2. PKC␤II induces its own expression in RIE cells. A, schematic
showing the three major splice variants of the PKC␤ gene. A single PKC␤I mRNA species is generated by exon exclusion. At least two PKC␤II mRNA species (␤IIa and ␤IIb) can be generated by alternative splicing of the final exon and 3Ј-untranslated region of the PKC␤ gene. B, PKC␤II induces expression of the PKC␤IIa and PKC␤IIb mRNA species but no detectable PKC␤I mRNA. Kinase-deficient PKC␤II does not induce endogenous PKC␤II expression. Rat brain is an abundant source of the PKC␤I, ␤IIa, and ␤IIb mRNA species and serves as a positive control. C, immunoblot analysis demonstrates that PKC␤II induces endogenous PKC␤II protein expression. Cell extracts from RIE and RIE/PKC␤II cells were subjected to immunoblot analysis using anti-PKC␤II and anti-FLAG antibodies. RIE/PKC␤II cells express two PKC␤II immunoreactive bands corresponding to the FLAG-tagged human PKC␤II transgenic protein (arrow) and endogenous rat PKC␤II (asterisk). Note that the lower migrating band comigrates with authentic rat brain PKC␤II. Anti-FLAG blotting confirms the identity of the higher migrating band as FLAG-tagged human PKC␤II.
LY317615-mediated inhibition of PKC␤ promoter activity in HCT116 cells is due to inhibition of PKC␤II. Endogenous PKC␤II mRNA levels in HCT116 cells are significantly reduced by both LY317615 and U0126, consistent with the effect of these compounds on PKC␤ promoter activity (Fig. 5B ). Our data demonstrate that PKC␤II expression is regulated through PKC␤II-mediated transcriptional control of the PKC␤ promoter in human colon cancer cell lines that express significant levels of PKC␤II. Our data further demonstrate that the PKC␤ promoter is regulated through a PKC␤II-, MEK1-, and MEK2-dependent pathway in these cells.
PKC␤II Regulates Its Own Expression in the Colonic
Epithelium in Vivo-We next assessed whether PKC␤II regulates its own expression in the colonic epithelium in vivo. For this purpose, we developed species-specific real time PCR assays to detect human and rodent PKC␤II (Fig. 6A) . We determined that our reagents are species-specific using RNA isolated from human K562 myelocytic leukemia cells and mouse brain as positive controls for human and mouse PKC␤II, respectively. The human PKC␤II reagents detect PKC␤II in K562 RNA but not in mouse brain RNA. Conversely, the mouse PKC␤II reagents detect abundant PKC␤II in mouse brain RNA but do not detect PKC␤II RNA in K562 cells.
Having demonstrated the specificity of our PCR reagents, we next assessed whether expression of human PKC␤II in the colonic epithelium of transgenic PKC␤II mice induces the expression of endogenous mouse PKC␤II in the colon (Fig. 6B) . In wild-type mice, we detect a low but detectable level of mouse PKC␤II mRNA in the colon, consistent with our previous immunohistochemical and immunoblot results demonstrating that PKC␤II is expressed at a relatively low level in the mouse colon (7). As expected, no human PKC␤II mRNA is detected in wild-type mice. However, in transgenic PKC␤II mice, we not only detect abundant transgenic human PKC␤II mRNA but also a much higher level of mouse PKC␤II mRNA when compared with wild-type mice. We next used RT-PCR reagents that distinguish the mouse PKC␤I and PKC␤II mRNA species of the PKC␤ gene to determine whether human PKC␤II induces one or the other of these variants preferentially (Fig. 6C) . In wildtype mice, we detect both PKC␤I and PKC␤II mRNA species, with PKC␤I mRNA being ϳ4-fold more abundant than PKC␤II mRNA. These results are consistent with our immunoblot analysis, which showed that PKC␤I is more abundant than PKC␤II in normal mouse colon tissue (7). In transgenic PKC␤II mice, we find that whereas the level of PKC␤I mRNA remains un- 
FIG. 6. PKC␤II induces its own expression in the colon in vivo.
A, characterization of real time PCR reagents that distinguish human and rodent PKC ␤II mRNAs. B, RNA from the colon of wild-type and transgenic PKC␤II mice was isolated and subjected to real time PCR analysis for human transgenic and endogenous mouse PKC␤II mRNA. C, real time PCR assays for mouse PKC␤I and PKC␤II were used to determine the level of PKC␤I and PKC␤II mRNA in wild-type and transgenic PKC␤II mice. changed, the level of PKC␤II mRNA is strongly induced. Thus, PKC␤II preferentially induces PKC␤II mRNA but not PKC␤I mRNA, consistent with our results in RIE/PKC␤II cells.
Finally, we wished to determine whether the induction of PKC␤II occurs in colonic epithelial cells and/or in surrounding mesenchymal cells. For this purpose, RNA isolated from colonic epithelial and mesenchymal cell fractions were subjected to QRT-PCR analysis for E-cadherin and vimentin mRNA, biochemical markers of epithelial and mesenchymal cells, respectively (Fig. 7A) . Epithelial cell preparations exhibited abundant E-cadherin mRNA but a very low level of vimentin mRNA. Conversely, mesenchymal cell preparations exhibited abundant vimentin but low levels of E-cadherin. These results indicate that these two cell fractions are highly enriched in epithelial and mesenchymal cells, respectively. Using our mouse PKC␤II-specific RT-PCR reagents, we observe that wild-type mice express ϳ3.5-fold higher levels of PKC␤II mRNA in the mesenchymal cell fraction than in the colonic epithelial cell fraction (Fig. 7B) . In transgenic PKC␤II mice, we find that whereas the level of PKC␤II mRNA in the colonic mesenchyme remains essentially unchanged, that in the colonic epithelium is much higher than in wild-type mice. Taken together, our results demonstrate that PKC␤II induces its own expression in the colonic epithelium in vivo. Autoinduction is selective for the PKC␤II splice variant(s) of the PKC␤ gene and is largely confined to the colonic epithelium. These data are consistent with the pattern of expression of the human PKC␤II transgene in these mice, which is confined to the colonic epithelium by virtue of the modified fatty acid-binding protein promoter construct driving transgene expression (8, 9, 22) . Our in vivo data are consistent with our results in RIE/PKC␤II and human colon cancer cells in vitro and suggest that similar mechanisms are involved in the autoregulation of PKC␤II in intestinal epithelial cells in vitro and in vivo. DISCUSSION PKC␤II has emerged as a critical gene involved in colon carcinogenesis (3, 7, 9 -12) . PKC␤II expression is elevated in early preneoplastic lesions and in established colon tumors in carcinogen-treated mice (7) . Expression of PKC␤II in the colon by transgenesis leads to colonic hyperproliferation and increased susceptibility to colon carcinogenesis (9, 11) . Here, we demonstrate that PKC␤ gene expression is a critical determinant of susceptibility to colon carcinogenesis. PKC␤KO mice exhibit resistance to AOM-induced ACF formation, preneoplastic lesions in the colon that are highly predictive of colon tumor formation (16, 17) . Significantly, reintroduction of PKC␤II expression to the colonic epithelium by transgenesis is sufficient to restore sensitivity to AOM in PKC␤KO mice. This observation provides strong genetic evidence that PKC␤II expression within the colonic epithelium is both necessary and sufficient to confer susceptibility to AOM-induced colon carcinogenesis in mice. These data are particularly interesting in light of the observation that PKC␤ may be important for tumor-mediated angiogenesis in other tumor systems (14) , a process that could be mediated by PKC␤ expressed in either epithelium-derived tumor cells, tumor-associated mesenchymal elements, or both. Although we cannot rule out a role for mesenchymal cell PKC␤II in the support of tumorigenesis, our data clearly demonstrate that expression of PKC␤II in colonic epithelial cells is critical for colon carcinogenesis. Our compound transgenic PKC␤KO/PKC␤II mice represent an important genetic model in which to assess the relative contribution of epithelial and stromal expression of PKC␤II in AOM-induced colon carcinogenesis. In addition, these mice will be useful in assessing the role of PKC␤II in other colon cancer models such as the APC min mouse.
Given the importance of epithelial PKC␤II in AOM-induced colon carcinogenesis, we assessed the mechanisms by which PKC␤II expression is regulated in RIE cells, human colon cancer cells, and the colonic epithelium in vivo. Microarray analysis identified the PKC␤ gene as a potential transcriptional target of PKC␤II in RIE/PKC␤II cells. Real time PCR analysis confirmed PKC␤ as a gene target for PKC␤II and demonstrated that autoregulation requires PKC␤II kinase activity. The PKC␤ gene is subject to regulation at both transcriptional and post-transcriptional levels (18, 20, 21, 23) . The PKC␤ gene encodes two distinct isoforms, PKC␤I and PKC␤II, which differ in their cellular function (3) . Abundant evidence indicates that the PKC␤ gene can be regulated through alternative splicing to yield multiple mRNA species (18 -20) . For example, insulin has been shown to induce a splicing switch from PKC␤I and PKC␤II isoforms that is mediated by alternative splicing mechanisms (19, 20) . However, our real time PCR analysis revealed no evidence for alternative splicing as a major mechanism controlling PKC␤ gene expression in RIE/ PKC␤II cells, human colon cancer cells, or the colonic epithelium. Indeed, PKC␤II appears to preferentially induce PKC␤II mRNAs in these tissues, with the three major PKC␤ mRNA species expressed to levels consistent with those expressed in rat brain. These results suggest that alternative splicing is not a major aspect of PKC␤II-mediated autoinduction. Analysis of two human PKC␤ promoter constructs demonstrates that transcriptional activation of the PKC␤ promoter is a major mechanism by which PKC␤II expression is regulated by PKC␤II in RIE and human colon cancer cells. The human PKC␤ promoter is induced by the presence of PKC␤II in RIE/ PKC␤II cells. We previously demonstrated that expression of PKC␤II in RIE cells activates cellular K-Ras and induces an invasive phenotype through activation of the small molecular weight GTPase and Ras effector, Rac1 (12) . PKC␤II-mediated Rac1 activation and cellular invasion are dependent upon MEK1 and -2 activity, demonstrating that PKC␤II induces invasion through a Ras 3 Rac 3 MEK signaling axis (12) . We also demonstrated that PKC␤II expression leads to loss of TGF␤ responsiveness in RIE/PKC␤II cells (10, 11) . PKC␤II mediates TGF␤ resistance through induction of Cox-2 gene expression (11) . Interestingly, PKC␤II autoinduction is blocked by inhibition of MEK1 and -2 activity but not by inhibition of Cox-2. These results indicate that the pathway by which PKC␤II induces TGF␤ resistance is distinct from that by which it induces cellular invasion and its own expression.
PKC␤II autoinduction is an important mechanism regulating PKC␤II expression in human colon cancer cells. HT29 cells express extremely low levels of PKC␤II mRNA and protein, whereas HCT116 cells express higher levels of PKC␤II. Consistent with the level of endogenous PKC␤II in these cell lines, HT29 cells support low PKC␤ promoter activity, whereas HCT116 cells support much higher PKC␤ promoter activity. PKC␤ promoter activity in HCT116 cells is blocked by the selective PKC␤ inhibitor LY317615 and the MEK1 and -2 inhibitor U0126, whereas that in HT29 cells is not significantly affected by PKC␤ or MEK1 and -2 inhibition.
Autoinduction of PKC␤II also occurs in the colonic epithelium in vivo. Expression of transgenic PKC␤II in the colonic epithelium of transgenic mice leads to induction of PKC␤II, but not PKC␤I, in the colonic epithelium. Our results reveal an important, novel mechanism by which PKC␤II expression may be regulated during AOM-induced colon carcinogenesis. It is interesting to note that dietary -6 fatty acids and secondary bile acids promote colon carcinogenesis and are potent activators of conventional PKC isozymes, including PKC␤II (24, 25) . Taken together with our data, one could envision a mechanism by which dietary risk factors can promote colon carcinogenesis by activating PKC␤II, which in turn induces its own expression through the autoregulatory mechanism described in the present study.
Numerous PKC isozymes have been implicated in various aspects of transformation. Recently, we demonstrated that atypical PKC is required for oncogenic Ras-mediated transformation both in vitro and in vivo (8) . PKC, like PKC␤II, is induced during colon carcinogenesis, and elevated expression of PKC leads to enhanced susceptibility to colon carcinogenesis, whereas disruption of PKC signaling blocks carcinogenesis (8) . Interestingly, at least one procarcinogenic pathway elucidated in our recent studies involves both PKC␤II and PKC. PKC is required downstream of Ras for PKC␤II-dependent invasion in RIE/PKC␤II cells (12) . In this regard, we recently demonstrated that both PKC␤II and PKC expression is induced in human chronic myelogenous leukemia cells (26) . Induction of PKC␤II and PKC expression in CML cells is dependent upon Bcr-Abl and the Ras/MEK pathway (26) . In CML cells, PKC induction is due to transcriptional activation of an ELK1-like element in the proximal PKC promoter (26) . Similar AP1 and AP2 sites have been implicated in the regulation of the PKC␤ promoter (21) . It will be of interest to determine whether PKC␤II autoregulation is dependent upon PKC and Rac1 activity, as is the case for PKC␤II-mediated invasion (12) .
Acquisition of an oncogenic K-Ras mutation, which occurs frequently in AOM-induced colon tumors and sporadic human colon cancers, could potentially activate PKC␤II autoinduction through activation of MEK1 and -2 activity. Consistent with this possibility, the human colon cancer cell lines examined in this study that harbor oncogenic Ras mutations, HCT116 and DLD-1 cells, both express relatively high levels of PKC␤II, whereas those that do not harbor oncogenic Ras mutations, HT29 and Caco2 cells, express very low levels of PKC␤II. It will be of interest to determine the prevalence of elevated PKC␤II expression in human colon cancers as a function of oncogenic Ras status and clinical outcome. Such a study is currently under way in our laboratory.
Finally, our results have important implications for the use of PKC␤ inhibitors as antineoplastic agents. Currently, LY317615 (also known as enzastaurin) is in phase 2 clinical trials for refractory large B-cell lymphoma and recurrent high grade glioma. Based on our cell-based and preclinical animal model studies, enzaspaurin is an attractive candidate for treatment and particularly prevention of colon cancer.
